Risk factors for inflammatory bowel disease: an umbrella review
- PMID: 39926114
- PMCID: PMC11802543
- DOI: 10.3389/fcimb.2024.1410506
Risk factors for inflammatory bowel disease: an umbrella review
Abstract
Introduction: Inflammatory bowel disease (IBD) represents a cluster of chronic idiopathic inflammatory disorders situated at the nexus of intricate interplays. The primary aim of the present investigation is to perform an umbrella review of metaanalyses, systematically offering a comprehensive overview of the evidence concerning risk factors for IBD.
Methods: To achieve this, we searched reputable databases, including PubMed, Embase, Web of Science, and the Cochrane Database of Systematic Reviews, from inception through April 2023. Two authors independently assessed the methodological quality of each metaanalysis using the AMSTAR tool and adhered to evidence classification criteria.
Results: In total, we extracted 191 unique risk factors in meta-analyses, including 92 significantly associated risk factors. The top ten risk factors were human cytomegalovirus (HCMV) infection, IBD family history, periodontal disease, poliomyelitis, campylobacter species infection, hidradenitis suppurativa, psoriasis, use of proton pump inhibitors, chronic obstructive pulmonary disease, and western dietary pattern.
Discussion: In conclusion, this umbrella review extracted 62 risk factors and 30 protective factors, most of which were related to underlying diseases, personal lifestyle and environmental factors. The findings in this paper help to develop better prevention and treatment measures to reduce the incidence of IBD, delay its progression, and reduce the burden of IBD-related disease worldwide.
Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42023417175.
Keywords: IBD; inflammatory bowel disease; meta-analysis; risk factor; umbrella review.
Copyright © 2025 Wu, Cheng, Zhuang, Liu, Ouyang and Qian.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Similar articles
-
Umbrella review of risk factors for inflammatory bowel disease: a study protocol.BMJ Open. 2024 Jun 25;14(6):e077267. doi: 10.1136/bmjopen-2023-077267. BMJ Open. 2024. PMID: 38925703 Free PMC article.
-
Incidence of and Risk Factors for Paradoxical Psoriasis or Psoriasiform Lesions in Inflammatory Bowel Disease Patients Receiving Anti-TNF Therapy: Systematic Review With Meta-Analysis.Front Immunol. 2022 Mar 1;13:847160. doi: 10.3389/fimmu.2022.847160. eCollection 2022. Front Immunol. 2022. PMID: 35300336 Free PMC article.
-
Hepatobiliary and pancreatic manifestations in inflammatory bowel disease: an umbrella review of meta-analyses.Therap Adv Gastroenterol. 2025 Jan 6;18:17562848241311165. doi: 10.1177/17562848241311165. eCollection 2025. Therap Adv Gastroenterol. 2025. PMID: 39777137 Free PMC article. Review.
-
Interventions for fatigue in inflammatory bowel disease.Cochrane Database Syst Rev. 2020 Apr 16;4(4):CD012005. doi: 10.1002/14651858.CD012005.pub2. Cochrane Database Syst Rev. 2020. PMID: 32297974 Free PMC article.
-
Diagnostic and prognostic value of echocardiography in pulmonary hypertension: an umbrella review of systematic reviews and meta-analyses.BMC Pulm Med. 2023 Jul 10;23(1):253. doi: 10.1186/s12890-023-02552-y. BMC Pulm Med. 2023. PMID: 37430308 Free PMC article.
Cited by
-
Obtainment of Flavonoid-Enriched Fractions from Maqui (Aristotelia chilensis) and Murta (Ugni molinae) Extracts via Preparative HPLC and Evaluation of Their Anti-Inflammatory Effects in Cell-Based Assays.Antioxidants (Basel). 2025 May 16;14(5):600. doi: 10.3390/antiox14050600. Antioxidants (Basel). 2025. PMID: 40427482 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous